Login to Your Account



Who badder on IPF ladder tough call until more data

By Randy Osborne
Staff Writer

Thursday, August 17, 2017

Fibrogen Inc.'s $326 million offering on the heels of Street-pleasing phase II data with pamrevlumab in IPF turned investor eyes to other prospects for the indication, prompting comparisons between them and attempts to stack pipeline candidates against two marketed products.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription